Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer

Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer

US Patent 10736921 · Granted Aug 11, 2020

Estimated economic value: $20,924,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combined invasion and cytotoxicity assay using chemokine secreting target cells2025
Combined invasion and cytotoxicity assay using chemokine secreting target cells2025
Modified NK-92 haNK003 cells for the clinic2025
Modified NK-92 haNK003 cells for the clinic2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-ex2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-ex2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-ex2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-ex2025
Fc-epsilon CAR2025
Fc-epsilon CAR2025
Method for treating SARS and treating or preventing ARDS2025
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derive2025